

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Martin Storck

Page 1/6

Tuesday, January 30, 2018

ROOM 3 - TECHNICAL FORUM

- 09:00 – 11:00** **Management of carotid artery disease: Remaining controversies and challenges ahead**
MODERATOR:
Marc van Sambeek
William Gray
PANEL:
Carlo Setacci
Stanislaw Bartus
Steve Ramee
- 09:00 – 09:07 Randomised data in carotid artery stenting: current evidence and future perspectives
Marco Roffi
- 09:07 – 09:12 Despite Level 1 and other evidence, the future outlook for carotid stenting is bright
Frank Veith
- 09:12 – 09:19 The future of carotid stenting – Proximal protection and mesh-covered stents are the answer
Stanislaw Bartus
- 09:19 – 09:44 Live case transmission from Berlin
Sankt-Gertrauden-Hospital Berlin - Live case center
- 09:44 – 09:51 1-year results of a new mesh-covered carotid stent: SCAFFOLD trial
William Gray
- 09:51 – 09:58 The CLEAR-ROAD study: a physician-initiated study investigating the RoadSaver stent in carotid lesions (final 12-month results)
Marc Bosiers
- 09:58 – 10:05 PrOspective multiCentrE study of cArotid artery steNting Using MER Stent – the OCEANUS study
Piotr Pieniazek
- 10:05 – 10:12 Comparative analysis of new mesh-covered stent designs using MRI parameters
Maria Antonella Ruffino
- 10:12 – 10:19 Plaque protrusion during carotid artery stenting: risk factors determined by MR plaque imaging
Katsutoshi Takayama

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Martin Storck

Page 2/6

Tuesday, January 30, 2018

- | | |
|---------------|---|
| 10:19 – 10:26 | ROADSTER 2 trial: Transcervical access with reversed flow circuit for proximal protection during CAS. What have we learned so far?
Peter Schneider |
| 10:26 – 10:33 | Transcervical carotid stenting (TECAR) with flow reversal vs. CEA in highly symptomatic patients
Ralf Kolvenbach |
| 10:33 – 11:00 | THE GREAT DEBATE: HOW SHOULD WE HANDLE ASYMPTOMATIC CAROTID STENOSES? |
| 10:33 – 10:40 | Carotid repair is best for asymptomatic severe carotid stenosis because medical management alone does not work
Peter Schneider |
| 10:40 – 10:47 | When better NOT to treat asymptomatic carotid stenosis
Martin Storck |
| 10:47 – 10:54 | ACST-2, over 2500 patients randomised; what do we know?
Alison Halliday |
| 10:54 – 11:00 | Discussion and conclusion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Martin Storck

Page 3/6

Tuesday, January 30, 2018

ROOM 3 - TECHNICAL FORUM

16:30 – 18:00 **SCRUB-IN WITH THE EXPERTS: Carotid interventions**

LIVE FROM LEIPZIG:

Andrej Schmidt

LIVE FROM COTIGNOLA:

Fausto Castriota

Antonio Micari

MODERATOR:

Giancarlo Biamino

Gary Ansel

PANEL:

Martin Storck

Carlo Setacci

Maria Antonella Ruffino

16:45 – 16:50 FLASH PRESENTATION: Current consideration for patient oriented revascularisation strategies: CAS vs. CEA vs. medical management
Carlo Setacci

17:00 – 17:05 FLASH PRESENTATION: How to integrate latest technology to make carotid stenting safer
Stephan Duda

17:15 – 17:20 FLASH PRESENTATION: Latest clinical experience with integrated embolic protection during CAS and future directions
Ravish Sachar

17:30 – 17:35 FLASH PRESENTATION: Combined carotid and coronary revascularisation: Is this a good idea?
George Chrysant

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Martin Storck

Page 4/6

Wednesday, January 31, 2018

ROOM 2 - MAIN ARENA 2

- 09:30 – 11:00** **EVAR – Current status, open questions, and future perspectives**
MODERATOR:
Frank Veith
Frans Moll
PANEL:
Sven Seifert
Jean-Pierre Becquemin
Martin Malina
Wei Guo
Roger Greenhalgh
Giovanni Torsello
- 09:30 – 09:36 Steps to clinical effectiveness and cost effectiveness – Lessons from EVAR 1
Fiona Rohlfss
- 09:36 – 09:42 Endovascular repair for patients physically unsuitable for open repair. EVAR 2 15-year results
Roger Greenhalgh
- 09:42 – 09:48 RCTs for EVAR: 15 years later are the conclusions obsolete?
Jean-Pierre Becquemin
- 09:48 – 09:54 How much open surgery is still required in aortic surgery: A review of 800 aortic aneurysm cases
Ralf Kolvenbach
- 09:54 – 10:00 Complex-anatomy large aneurysms and why we should consider use of no-treatment and open-surgery strategies more frequently
Frank Criado
- 10:00 – 10:05 Role of gender in TEVAR and EVAR: report from the GREAT registry
Mauro Gargiulo
- 10:05 – 10:10 Long-term outcomes of EVAR in female patients: A 5-year analysis from the ENGAGE registry
Giovanni Pratesi
- 10:10 – 10:40 Live case transmission from Leipzig
University Hospital Leipzig, Dep. Angiology - Live case center
- 10:40 – 10:45 Ovation endograft: 4-year, real world results from the Ovation European post market registry
Martin Storck

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Martin Storck

Page 5/6

Wednesday, January 31, 2018

- | | |
|---------------|---|
| 10:45 – 10:50 | 10-year outcome analysis of the ITER registry with the GORE Excluder® endograft for infrarenal abdominal aortic aneurysms
Giovanni Pratesi |
| 10:50 – 10:55 | Predictors of abdominal aortic aneurysm sac enlargement after EVAR; long-term results from the ENGAGE registry
Dittmar Böckler |
| 10:55 – 11:00 | Discussion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Martin Storck

Page 6/6

Wednesday, January 31, 2018

ROOM 2 - MAIN ARENA 2

- 12:30 – 13:30** **LUNCH SYMPOSIUM: Advancing EVAR: Access more AAA patients and customise each seal**
supported with an educational grant from Endologix
MODERATOR:
Andrew Holden
PANEL:
Eric Verhoeven
Sean Lyden
Martin Storck
- 12:30 – 12:40 Impact of infrarenal neck diameter on midterm outcome following EVAR: Considerations for repair choice and surveillance
Eric Verhoeven
- 12:40 – 12:50 Finally, an ultra-low profile endograft that is not a tradeoff: Deliverability, patency, and durability of the Ovation® platform
Sean Lyden
- 12:50 – 13:00 Why Ovation® may improve EVAR outcomes in women
Martin Storck
- 13:00 – 13:25 Recorded case presentation
Sigrid Nikol
- 13:25 – 13:30 Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.